New York, New York--(Newsfile Corp. - March 10, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Oracle Corporation (NYSE: ORCL) between June 12, 2025, and December 16, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline.SO WHAT: If you purchased Oracle common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. ...

Core Viewpoint - A class action lawsuit has been filed against Snowflake Inc. on behalf of purchasers of Class A common stock during the specified Class Period, alleging that the company made misleading positive statements about its business while failing to disclose material negative impacts on consumption and revenues [1][5]. Group 1: Lawsuit Details - The class action lawsuit covers purchasers of Snowflake Class A common stock from June 27, 2023, to February 28, 2024 [1]. - The lawsuit claims that during the Class Period, Snowflake's management made positive statements regarding customer usage and product developments, which were later revealed to lack a reasonable basis due to undisclosed negative impacts on consumption and revenues [5]. Group 2: Participation Information - Investors who purchased Snowflake Class A common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm directly for more information [3][6]. Group 3: Law Firm Credentials - The Rosen Law Firm, which is leading the class action, has a strong track record in securities class actions and has recovered hundreds of millions of dollars for investors [4]. - The firm was ranked No. 1 for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013 [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Enphase Energy, Inc. securities between April 22, 2025, and October 28, 2025, of the April 20, 2026, deadline to become a lead plaintiff in a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Enphase securities during the specified period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [2][5]. - The deadline to move the Court to serve as lead plaintiff is April 20, 2026 [2]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [3]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company and has been ranked highly for its success in this area [3]. Group 3: Case Allegations - The lawsuit alleges that Enphase made false and misleading statements regarding its inventory management and financial prospects, which led to investor damages when the truth was revealed [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Smart Digital Group Ltd. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][3]. Group 1: Class Action Details - Investors who purchased SDM securities between May 5, 2025, and September 26, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by March 16, 2026 [3]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. Group 3: Case Allegations - The lawsuit alleges that Smart Digital was involved in a market manipulation scheme, including misinformation on social media and insider trading practices [5]. - It is claimed that Smart Digital's public statements failed to disclose risks related to fraudulent trading, leading to misleading information about the company's business and operations [5].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of DNOW Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Legal Action and Investor Rights - Shareholders who purchased DNOW securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees, facilitated by a contingency fee arrangement [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses related to DNOW [2]. Group 2: Financial Performance and Market Reaction - DNOW shares experienced a significant decline of 19.1% on February 20, 2026, following the release of disappointing fourth-quarter 2025 financial results, which included a substantial loss and missed Wall Street expectations [3]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone, and has consistently ranked in the top 4 for securities class action settlements since 2013 [4].

New York, New York--(Newsfile Corp. - March 7, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Corcept Therapeutics Incorporated (NASDAQ: CORT) between October 31, 2024 and December 30, 2025, inclusive (the "Class Period"), of the important April 21, 2026 lead plaintiff deadline.SO WHAT: If you purchased Corcept common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingen ...

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Banco Santander, S.A. due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation and Legal Action - The investigation is prompted by concerns that Santander may have misled investors, leading to a class action seeking recovery of investor losses [2]. - Investors who purchased Santander securities may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Market Impact - On February 27, 2026, Santander's American Depositary Shares (ADSs) fell by 4.48%, followed by a further decline of 3.2% on February 28, 2026, in response to news regarding potential losses from the collapse of a UK mortgage provider [4]. Group 3: Context of the Investigation - The investigation follows a Reuters article highlighting concerns about wider losses among banks due to the collapse of Market Financial Solutions Ltd, a UK mortgage provider, which has raised fears of more issues within the private credit industry [3].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased BlackRock TCP Capital Corp. securities during the specified class period of the upcoming lead plaintiff deadline on April 6, 2026 [1]. Group 1: Class Action Details - Investors who bought BlackRock TCP securities between November 6, 2024, and January 23, 2026, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - To serve as lead plaintiff, individuals must file a motion with the court by April 6, 2026 [3]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been ranked highly for its number of securities class action settlements, recovering hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, highlighting the firm's expertise and reputation in the field [4]. Group 3: Case Allegations - The lawsuit alleges that defendants made materially false and misleading statements regarding BlackRock TCP's business and operations, including issues with the timely valuation of investments and ineffective portfolio restructuring [5]. - It is claimed that these misrepresentations led to understated unrealized losses and overstated net asset value, ultimately misleading investors about the company's prospects [5]. - The lawsuit asserts that when the true information became public, investors suffered damages as a result [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Ultragenyx Pharmaceutical Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Ultragenyx common stock between August 3, 2023, and December 26, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 6, 2026 [3]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been ranked highly for its number of securities class action settlements and has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. Group 3: Case Background - The lawsuit alleges that Ultragenyx's defendants provided misleading information regarding the expected results of their Phase III studies for setrusumab (UX 143) in treating Osteogenesis Imperfecta [5]. - It is claimed that while setrusumab increases bone density, it does not correlate with a decrease in annualized fracture rates, contrary to the positive statements made by the defendants [6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Corcept Therapeutics Incorporated during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Corcept common stock between October 31, 2024, and December 30, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 21, 2026 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in this area [4]. - The firm has achieved significant settlements for investors, including over $438 million in 2019, and has been recognized as a leader in securities class action settlements [4]. Group 3: Case Background - The lawsuit alleges that Corcept misrepresented the strength of clinical trials supporting the New Drug Application (NDA) for relacorilant, claiming it was a "powerful support" for FDA approval [5]. - It is claimed that the FDA had raised concerns about the clinical evidence for the NDA, indicating a material risk of non-approval, which was not disclosed to investors [5].